Inhibiting BRAF Oncogene-Mediated Radioresistance Effectively Radiosensitizes BRAFV600E-Mutant Thyroid Cancer Cells by Constraining DNA Double-Strand Break Repair.

Ryan RobbLinlin YangChangxian ShenAdam R WolfeAmy WebbXiaoli ZhangMarall VedaieMotoyasu SajiSissy JhiangMatthew D RingelTerence M Williams

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

BRAFV600E mutation promotes NHEJ activity leading to radioresistance and BRAFi selectively radiosensitizes BRAFV600E thyroid cancer cells through inhibiting NHEJ. Our findings suggest that combining BRAFi and radiation may improve the therapeutic outcome of patients with BRAFV600E-mutant thyroid cancer.

Keyphrases

wild type
signaling pathway
dna damage response
cancer stem cells
oxidative stress
nucleic acid